Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

被引：0
|
作者：
Gross-Goupil, M. [1 ]
Kwon, T. G. [2 ]
Eto, M. [3 ]
Ye, D. [4 ]
Miyake, H. [5 ]
Seo, S. I. [6 ]
Byun, S. S. [7 ]
Lee, J. L. [8 ]
Master, V. [9 ]
Jin, J. [10 ]
Debenedetto, R. [11 ]
Linke, R. [12 ]
Casey, M. [13 ]
Rosbrook, B. [14 ]
Frean, M. J. Lechuga [15 ]
Valota, O. [16 ]
Grande, E. [17 ]
Quinn, D. I. [18 ]
机构：
[1] Hop St Andre, Dept Oncol, CHU Bordeaux, Bordeaux, France
[2] Kyungpook Natl Univ, Sch Med, Daegu, South Korea
[3] Kyushu Univ, Dept Clin Med, Fukuoka, Fukuoka, Japan
[4] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Hamamatsu Univ, Sch Med, Hamamatsu, Shizuoka, Japan
[6] Sungkyunkwan Univ, Dept Urol, Seoul, South Korea
[7] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[8] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[9] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA
[10] Peking Univ, Dept Urol, Hosp 1, Beijing, Peoples R China
[11] SFJ Pharmaceut, Clin Dev & Med Affairs, Pleasanton, CA USA
[12] SFJ Pharmaceut Inc, Clin Dev & Med Affairs, Pleasanton, CA USA
[13] Pfizer Inc, Dept Oncol, Collegeville, PA USA
[14] Pfizer Inc, Translat Oncol, La Jolla, CA USA
[15] Pfizer Italia Srl, Dept Oncol, Milan, Italy
[16] Pfizer Srl, Dept Oncol, Milan, Italy
[17] MD Anderson Canc Ctr Ctr Espana, Dept Med Oncol, Madrid, Spain
[18] Univ Southern Calif, Translat & Clin Sci Program, Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
863O
引用
收藏
页码：303 / 303
页数：1
相关论文
共 50 条
  • [31] ASET STUDY: FINAL RESULTS OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC RENAL CELL CARCINOMA (RCC) TREATED WITH MGN1601
    Gruenwald, V.
    Weikert, S.
    Schmidt-Wolf, I.
    Hauser, S.
    Magheli, A.
    Kapp, K.
    Schroff, M.
    Schmidt, M.
    Wittig, B.
    ANNALS OF ONCOLOGY, 2014, 25
  • [32] Phase-II trial of thalidomide for patients with metastatic renal cell carcinoma (RCC).
    Green, D
    Meza-Junco, J
    Arce, C
    Chavez-Macgregor, M
    de la Peña, R
    Sotomayor, M
    Gabilondo, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 443S - 443S
  • [33] Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial
    Staehler, M.
    Motzer, R. J.
    George, D. J.
    Pandha, H. S.
    Donskov, F.
    Escudier, B.
    Kliment, J.
    Pantuck, A. J.
    Patel, A.
    Deannuntis, L.
    Bhattacharyya, H.
    Lin, X.
    Lechuga, M.
    Serfass, L.
    Patard, J-J.
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial
    Ciccarese, C.
    Porcari, S.
    Buti, S.
    Fornarini, G.
    Primi, F.
    Giudice, G. C.
    Damassi, A.
    Berrios, J. R. Giron
    Stumbo, L.
    Arduini, D.
    Severino, A.
    Rondinella, D.
    Masucci, L.
    Sanguinetti, M.
    Gasbarrini, A.
    Cammarota, G.
    Segata, N.
    Tortora, G.
    Ianiro, G.
    Iacovelli, R.
    ANNALS OF ONCOLOGY, 2024, 35 : 1264 - 1264
  • [35] Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
    Rini, Brian I.
    Garrett, May
    Poland, Bill
    Dutcher, Janice P.
    Rixe, Olivier
    Wilding, George
    Stadler, Walter M.
    Pithavala, Yazdi K.
    Kim, Sinil
    Tarazi, Jamal
    Motzer, Robert J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (05): : 491 - 504
  • [36] Phase 3 study of pembrolizumab vs placebo as adjuvant therapy for patients with renal cell carcinoma (RCC): KEYNOTE-564 Asia subset
    Park, Se Hoon
    Chang, Yen-Hwa
    Lee, Jae Lyun
    Kitamura, Hiroshi
    Chung, Jinsoo
    Nishimura, Kazuo
    Kato, Minoru
    Kato, Haruaki
    Kimura, Go
    Masumori, Naoya
    Chiu, Kun-Yuan
    Chang, Chao-Hsiang
    Numakura, Kazuyuki
    Chen Chang
    Burgents, Joseph E.
    Willemann-Rogerio, Jaqueline
    Choueiri, Toni
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 63 - 64
  • [37] Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
    Karam, Jose A.
    Devine, Catherine E.
    Urbauer, Diana L.
    Lozano, Marisa
    Maity, Tapati
    Ahrar, Kamran
    Tamboli, Pheroze
    Tannir, Nizar M.
    Wood, Christopher G.
    EUROPEAN UROLOGY, 2014, 66 (05) : 874 - 880
  • [38] Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma
    Karam, Jose A.
    Devine, Catherine E.
    Urbauer, Diana L.
    Lozano, Marisa
    Ahrar, Kamran
    Tamboli, Pheroze
    Tannir, Nizar M.
    Wood, Christopher G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [39] FIRST RESULTS OF A-PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY
    Stewart, Grant
    Morden, James
    Boleti, Ekaterini
    Vasudev, Naveen
    Thistlethwaite, Fiona
    Michael, Agnieszka
    Kilburn, Lucy
    Lewis, Rebecca
    Nicol, David
    Pyle, Linda
    Snowdon, Claire
    Todd, Rachel
    Tregellas, Lucy
    Turajlic, Samra
    Swanton, Charlie
    Bliss, Judith
    Larkin, James
    JOURNAL OF UROLOGY, 2017, 197 (04): : E917 - E917
  • [40] Sorafenib in advanced renal cell carcinoma (RCC): Survival and biomarker results from a phase III trial
    Bukowski, R.
    Hong, D.
    Eisen, T.
    Szczylik, C.
    Stadler, W. M.
    Porte, C.
    Simantov, R.
    Shan, M.
    Elting, J.
    Pena, C.
    Escudier, B.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 245 - 245
12345